Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 17/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16178464 | 0.81 | PI4KB (0.48) | PI4KBKCNH2 | |
| SCHEMBL14948613 | 0.81 | PI4KB (0.48) | PI4KBKCNH2 | |
| Hydrochloric Acid SCHEMBL16178577 | 0.80 | PI4KB (0.47) | PI4KBKCNH2 | |
| SCHEMBL16178571 | 0.79 | PI4KB (0.48) | PI4KBKCNH2 | |
| SCHEMBL17993458 | 0.78 | PI4KB (0.56) | PI4KBKCNH2 | |
| SCHEMBL16178451 | 0.77 | PI4KB (0.52) | PI4KBKCNH2 | |
| SCHEMBL16177992 | 0.76 | HRH4 (0.51) | PI4KB | |
| SCHEMBL16178448 | 0.72 | PI4KB (0.66) | PI4KBKCNH2 | |
| SCHEMBL16177933 | 0.72 | PI4KB (0.66) | PI4KBKCNH2 | |
| SCHEMBL16178476 | 0.70 | PI4KB (0.64) | PI4KBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776445-B1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-08-10 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | PI4KB 800/4885KCNH2 2680/4885PIM1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.